Dr. Schuster discusses trial of 18F-rhPSMA-7.3 in prostate cancer
In this video, David M. Schuster, MD, FACR, discusses the background and findings of the study, “Detection rates of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT),” which was presented at the 2022 ASCO Genitourinary Cancers Symposium. Schuster is a professor of urology and radiology and imaging sciences, a GRA distinguished cancer scientist, and the director of the division of nuclear medicine and molecular imaging at the Emory University School of Medicine in Atlanta, Georgia.
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.
